Beyond
the Biobucks

What became of China's biggest pharma licensing deals, and what risks buyers took on.

The Series

One deal per post.
What happened next.

Layout preview: the same post is shown ten times.

The Terminal

The headline number
is a promise.

When a Chinese biotech licenses a drug to a Western buyer, the press release leads with one figure in the billions. Most of it is conditional. The terminal follows each deal after the signature: payments confirmed by a public source, trials started, programmes dropped, rights returned. A date slider rewinds every deal to what was public on that day.

50
deals tracked
$126.4B
announced
$3.6B
confirmed paid in public sources
12
ended or cut back
Open the terminal →

Figures pending review

Method

How the numbers
are built.

Announced
The upfront plus every milestone the announcement mentions. It is the ceiling of the deal, reached only if every trial, filing and sales target succeeds.
Confirmed paid
Payments that a public document says were made or received: a regulatory filing, a stock-exchange announcement, a company release. Without such a document the deal shows n/d, never zero.
Status
Active, partly returned or terminated. It is read from the dated events of each deal: a termination, rights handed back, a programme dropped.
As of
The terminal can rewind to any month. An event counts from the date of the source that reports it, so a payment made in 2021 and disclosed in a 2023 filing appears in 2023.
Sources
Public documents only. Filings, company releases and trial registries come first; trade press is used as a secondary source and labelled as such.
Limits
Each deal is entered by hand, one file per deal. The files are still waiting for a second review, so figures may change. This is descriptive research, not investment advice.